Hansa Biopharma: increase in number of shares and votes

28 Jun 2024
www.prnewswire.com
LUND, Sweden, June 28, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa Biopharma" or the "Company") (NASDAQ: HNSA) (STOCKHOLM: HNSA) today announced that Hansa's registered share capital and number of shares and votes have increased through (i) the issue of 2,305,260 new ordinary shares resolved on 12 April 2024 and registered with the Swedish Companies Registration Office during June 2024, whereby the number of votes increased with 2,305,260 and the share capital increased with SEK 2,305,260, and (ii) conversion of all 2,362,445 issued class C shares in Hansa to a total of 2,362,445 ordinary shares, in order to deliver ordinary shares to participants in Hansa's outstanding incentive programs and to secure social contributions arising as a result of the incentive programs.
As of today, the total number of registered shares of Hansa amounts to 67,814,241, of which all are ordinary shares. As of today, the number of votes in Hansa amounts to 67,814,241, and the registered share capital amounts to SEK 67,814,241.
This disclosure contains information that Hansa Biopharma AB is obliged to make public pursuant to the Swedish Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact persons below, on June 28, 2024 at 07:00 CEST.
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
[email protected]
Stephanie Kenney, VP Global Corporate Affairs
[email protected]
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. Hansa Biopharma has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa Biopharma has a rich and expanding research and development program based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.
©2024 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma--increase-in-number-of-shares-and-votes,c4003536
The following files are available for download:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.